- Home
- BBIO vs ASND Comparison
BBIO vs ASND Comparison
Compare BBIO & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | ASND |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 12.8B |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BBIO | ASND |
|---|---|---|
| Price | $74.32 | $208.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 16 |
| Target Price | $78.43 | ★ $260.69 |
| AVG Volume (30 Days) | ★ 1.9M | 702.4K |
| Earning Date | 02-19-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $353,780,000.00 | ★ $758,592,045.00 |
| Revenue This Year | $127.64 | $98.90 |
| Revenue Next Year | $78.38 | $83.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 62.46 | ★ 97.46 |
| 52 Week Low | $28.10 | $118.03 |
| 52 Week High | $78.59 | $229.94 |
Technical Indicators
Market Signals| Indicator | BBIO | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 49.47 |
| Support Level | $71.19 | $204.50 |
| Resistance Level | $75.57 | $219.27 |
| Average True Range (ATR) | 2.44 | 7.51 |
| MACD | -0.65 | 0.04 |
| Stochastic Oscillator | 38.54 | 51.35 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.